Tracked deals
20
20 tracked deals across 2020-2026.
Public Company
Healthcare
Eli Lilly and Company
Indianapolis, Indiana, United States
Eli Lilly and Company is a medicine company using biotechnology, chemistry, and genetic medicine to advance science and address major health challenges.
- Focus Areas
- Pharmaceuticals, Biotechnology, Genetic medicine
- Website
- lilly.com
Recent pace
12
12 tracked deals announced in the last 12 months.
Deal mix
Buyout
19 buyout · 1 growth capital
Eli Lilly and Company Acquisition Volume by Year
Last 5 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
Showing the 12 most recent of 20 tracked deals for Eli Lilly and Company.
-
July 17, 2026
- Buyer
- Eli Lilly and Company
- Target
- AtaiBeckley Inc.
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Eli Lilly and Company has signed a definitive agreement to acquire AtaiBeckley, a clinical-stage biopharmaceutical company focused on rapid-acting mental health therapies. The upfront consideration is $6.75 per share in cash (aggregate equity value of about $2.8 billion) plus up to $2.50 per share via contingent value rights tied to development and regulatory milestones.
-
June 16, 2026
- Buyer
- Eli Lilly and Company
- Target
- 4E Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Texas, United States
- Type
- Buyout
Eli Lilly and Company acquired Austin-based neuroscience company 4E Therapeutics to advance its non-opioid chronic pain pipeline. 4E is developing orally available MNK inhibitors targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, including lead candidate 4ET1103 that entered human Phase 1 trials with a favorable safety profile.
-
- Buyer
- Eli Lilly and Company
- Target
- Vaccine Company, Inc.
- Industry
- Biotechnology
- Location
- Maryland, United States
- Type
- Buyout
Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.
-
- Buyer
- Eli Lilly and Company
- Target
- Curevo Vaccine (Curevo), LimmaTech Biologics AG (LimmaTech Biologics)
- Industry
- Pharmaceuticals
- Location
- Switzerland
- Type
- Buyout
Eli Lilly entered definitive agreements to acquire Curevo Vaccine and LimmaTech Biologics as part of a broader expansion of its infectious disease R&D platform. Lilly will acquire Curevo for up to $1.5 billion and LimmaTech Biologics for up to $780 million, with upfront and additional milestone-based payments.
-
May 23, 2026
- Buyer
- Eli Lilly and Company
- Target
- Engage Biologics Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Eli Lilly and Company has acquired Engage Biologics in a deal valued at up to $202 million in cash, including an upfront payment and milestone-based payments. The acquisition is intended to strengthen Lilly’s genetic medicines capabilities by integrating Engage’s non-viral DNA delivery Tethosome platform with Lilly’s broader development portfolio.
-
April 28, 2026
- Buyer
- Eli Lilly
- Target
- Profluent
- Industry
- Biotechnology
- Type
- Growth capital
Air Street Capital portfolio company Profluent announced a multi-program strategic partnership with Eli Lilly to develop AI-designed recombinases for genetic medicine. Profluent will receive an upfront payment, committed R&D funding, and is eligible for up to $2.25 billion in development and commercial milestones, plus tiered royalties on net sales.
-
April 27, 2026
- Buyer
- Eli Lilly and Company
- Target
- Ajax Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
Eli Lilly and Company announced a definitive agreement to acquire Ajax Therapeutics, Inc. in a deal valued at up to $2.3 billion, including upfront and milestone-based payments. The acquisition is intended to expand Lilly’s oncology pipeline with Ajax’s lead candidate, AJ1-11095, a Type II JAK2 inhibitor in Phase 1 development for myelofibrosis, including patients previously treated with Type I JAK2 inhibitors.
-
April 20, 2026
- Buyer
- Eli Lilly and Company, Eli Lilly
- Target
- Kelonia Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Eli Lilly has announced a definitive agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company developing in vivo CAR-T cell therapy via its proprietary gene delivery platform. The deal is valued at up to $7 billion, including a $3.25 billion upfront payment, with additional clinical, regulatory, and commercial milestone payments. Closing is expected in the second half of 2026, subject to customary approvals.
-
April 14, 2026
- Buyer
- Eli Lilly and Company
- Target
- CrossBridge Bio
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Eli Lilly and Company has entered into a definitive agreement to acquire CrossBridge Bio, a Houston-based pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs). The deal provides for up to $300 million in total consideration, including upfront and milestone-based payments, to advance CrossBridge Bio’s TROP2-targeting TOP1i/ATRi ADC platform led by CBB-120.
-
March 31, 2026
- Buyer
- Eli Lilly and Company
- Target
- Centessa Pharmaceuticals plc
- Seller
- a group of shareholders
- Industry
- Biotechnology
- Location
- United Kingdom
- Type
- Buyout
Eli Lilly and Company entered into a definitive agreement to acquire clinical-stage biopharma Centessa Pharmaceuticals plc for $38.00 per share in cash, plus a non-transferrable contingent value right (CVR) that could bring total consideration to up to $47.00 per share. The deal is structured as a scheme of arrangement under the laws of England and Wales and was expected to close in Q3 2026, subject to shareholder and regulatory approvals and court sanction.
-
February 9, 2026
- Buyer
- Eli Lilly and Company
- Target
- Orna Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Eli Lilly and Company has signed a definitive agreement to acquire Orna Therapeutics, valuing the deal at up to $2.4 billion. The acquisition is intended to expand Lilly’s genetic medicine and in vivo cell engineering capabilities, particularly for advancing in vivo CAR-T therapies using Orna’s circular RNA and lipid nanoparticle (LNP) platform.
-
January 8, 2026
- Buyer
- Eli Lilly and Company
- Target
- Ventyx Biosciences
- Seller
- Entities affiliated with New Science Ventures, Ventyx directors and officers (including through voting/support agreements)
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
16 tracked deals by Eli Lilly and Company.
Pharmaceuticals Buyers & Acquisitions
4 tracked deals by Eli Lilly and Company.
Acquisitions in Massachusetts
5 tracked deals by Eli Lilly and Company.
Acquisitions in California
4 tracked deals by Eli Lilly and Company.
Acquisitions in New York
3 tracked deals by Eli Lilly and Company.
Acquisitions in Texas
2 tracked deals by Eli Lilly and Company.
Selling a company? Get in front of buyers like Eli Lilly and Company
Turn tracked acquisition activity into an outreach-ready buyer list.